Technical Analysis for ACRX - AcelRx Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 2.65 1.53% 0.04
ACRX closed up 1.53 percent on Wednesday, September 18, 2019, on 76 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical ACRX trend table...

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
New Uptrend Bullish 1.53%
Upper Bollinger Band Walk Strength 1.53%
Weak + Overbought Other 1.53%
Overbought Stochastic Strength 1.53%
Upper Bollinger Band Touch Strength 1.53%
50 DMA Support Bullish -2.57%

Older signals for ACRX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company's principal product candidate is ARX-01, a Sufentanil NanoTab PCA system, which is in Phase III clinical trials for acute post-operative pain in patients in the hospital setting. Its product candidates also comprise ARX-02, a Sufentanil NanoTab BTP management system that has completed a Phase II clinical trial for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which has completed a Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician's office. In addition, the company's product candidate under development includes ARX-04, a Sufentanil Single-Dose NanoTab for the treatment of patients with moderate-to-severe acute pain either on the battlefield or in civilian settings of trauma or injury. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Chemistry Cancer Pain Chemical Compounds Organic Compounds Treatment Of Cancer Clinical Trial Ethers Injury Piperidines Fentanyl Stage Specialty Pharmaceutical Breakthrough Pain Sufentanil Thiophenes
Is ACRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 5.05
52 Week Low 1.99
Average Volume 964,366
200-Day Moving Average 2.8017
50-Day Moving Average 2.4688
20-Day Moving Average 2.371
10-Day Moving Average 2.495
Average True Range 0.1478
ADX 26.9
+DI 25.5979
-DI 11.1369
Chandelier Exit (Long, 3 ATRs ) 2.3566
Chandelier Exit (Short, 3 ATRs ) 2.5034
Upper Bollinger Band 2.6945
Lower Bollinger Band 2.0475
Percent B (%b) 0.93
BandWidth 27.288064
MACD Line 0.0649
MACD Signal Line 0.0176
MACD Histogram 0.0473
Fundamentals Value
Market Cap 120.25 Million
Num Shares 45.4 Million
EPS -1.10
Price-to-Earnings (P/E) Ratio -2.41
Price-to-Sales 5.25
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.91
Resistance 3 (R3) 2.90 2.81 2.86
Resistance 2 (R2) 2.81 2.75 2.81 2.85
Resistance 1 (R1) 2.73 2.70 2.77 2.74 2.83
Pivot Point 2.64 2.64 2.66 2.64 2.64
Support 1 (S1) 2.56 2.58 2.60 2.57 2.47
Support 2 (S2) 2.47 2.53 2.47 2.45
Support 3 (S3) 2.39 2.47 2.44
Support 4 (S4) 2.40